ATE553778T1 - Für humanes hepcidin spezifische antikörper - Google Patents

Für humanes hepcidin spezifische antikörper

Info

Publication number
ATE553778T1
ATE553778T1 AT08835406T AT08835406T ATE553778T1 AT E553778 T1 ATE553778 T1 AT E553778T1 AT 08835406 T AT08835406 T AT 08835406T AT 08835406 T AT08835406 T AT 08835406T AT E553778 T1 ATE553778 T1 AT E553778T1
Authority
AT
Austria
Prior art keywords
antibodies specific
human hepcidin
hepcidin
human
antigen
Prior art date
Application number
AT08835406T
Other languages
English (en)
Inventor
Sophie Vaulont
Hugues Gascan
Josy Froger
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE553778T1 publication Critical patent/ATE553778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT08835406T 2007-10-02 2008-10-02 Für humanes hepcidin spezifische antikörper ATE553778T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291196 2007-10-02
PCT/IB2008/003310 WO2009044284A1 (en) 2007-10-02 2008-10-02 Antibodies specific for human hepcidin

Publications (1)

Publication Number Publication Date
ATE553778T1 true ATE553778T1 (de) 2012-05-15

Family

ID=38983917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08835406T ATE553778T1 (de) 2007-10-02 2008-10-02 Für humanes hepcidin spezifische antikörper

Country Status (8)

Country Link
US (1) US8487081B2 (de)
EP (1) EP2200647B1 (de)
JP (1) JP2010539969A (de)
CN (1) CN101903044A (de)
AT (1) ATE553778T1 (de)
CA (1) CA2701694A1 (de)
ES (1) ES2385772T3 (de)
WO (1) WO2009044284A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392345B2 (de) * 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE553778T1 (de) 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
AR069062A1 (es) 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
US9315577B2 (en) * 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2328931B1 (de) 2008-08-06 2013-08-14 Eli Lilly And Company Selektive anti-hepcidin-25-antikörper und anwendungen davon
DE102009034150A1 (de) * 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
US20120196853A1 (en) 2009-08-20 2012-08-02 Vifor (International) Ag Novel Quinoline-Hepcidine Antagonists
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
EP2475643A1 (de) 2009-09-07 2012-07-18 Vifor (International) Ag Neue ethandiamin-hepcidin-antagonisten
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2022154121A1 (ja) * 2021-01-18 2022-07-21 富士フイルム和光純薬株式会社 ヘプシジンの吸着抑制剤、吸着抑制方法、標準品、試薬、キットおよび測定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1392345B2 (de) 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
RU2359268C2 (ru) 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
ATE553778T1 (de) 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper

Also Published As

Publication number Publication date
US8487081B2 (en) 2013-07-16
ES2385772T3 (es) 2012-07-31
EP2200647B1 (de) 2012-04-18
EP2200647A1 (de) 2010-06-30
CN101903044A (zh) 2010-12-01
WO2009044284A1 (en) 2009-04-09
JP2010539969A (ja) 2010-12-24
CA2701694A1 (en) 2009-04-09
US20100285027A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CU24058B1 (es) Antagonistas de pcsk9
EA201370081A1 (ru) Антитела к cd48 и их применение
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
ECSP10010297A (es) Anticuerpos bivalentes biespecíficos
BR112012007365A2 (pt) proteínas de ligação à il-1
ECSP12011885A (es) Inmunoglobulinas con dominio variable dual
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201790757A1 (ru) Связывающие антиген cd27l белки
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
MY177564A (en) Anti-nr10 antibody and use thereof
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF